KD 5170 (S-[2-[6-[[[4-[3-(Dimethylamino)propoxy]phenyl]sulfonyl]amino]-3-pyridinyl]-2-oxoethyl]ethanethioc acid ester) | 940943-37-3

name

kd 5170

chemical name

s-[2-[6-[[[4-[3-(dimethylamino)propoxy]phenyl]sulfonyl]amino]-3-pyridinyl]-2-oxoethyl]ethanethioc acid ester

activity

class i and ii histone deacetylase (hdac) inhibitor (ic50 = 0.045 μm; ec50 = 0.025 μm in hela screening and hela cell-based assays, respectively). exhibits broad spectrum inhibition of hdac classes i and ii in assays using purified recombinant human isoforms. displays less potent inhibition of hdac2 (ic50 values are 0.014, 0.020, 0.026, 0.075 and 2.0 μm for hdac6, hdac1, hdac4, hdac3 and hdac2 respectively). displays cytotoxicity against numerous cell lines derived from human tumors. orally available.

MW

451.56

Formula:

c20h25n3o5s2

Solubility:

soluble to 100 mm in 1eq. hcl and to 100 mm in dmso

Purity:

>95 %

Storage:

store at -20°c

CAS No:

940943-37-3

Feng et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol.Cancer Ther. 7 1494. PMID: 18566220.

Hassig et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad-spectrum antitumor activity in vitro and in vivo. Mol.Cancer Ther. 7 1054. PMID: 18483295.

Payne et al (2008) Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg.Med.Chem.Lett. 18 6093. PMID: 18954983.